MediWound Ltd. is a specialized biopharmaceutical company focused on developing, manufacturing, and commercializing proprietary enzymatic therapeutics designed for non-surgical tissue repair and regenerative medicine. Its core technology utilizes proteolytic enzymes derived from pineapple stems to selectively target and remove damaged tissue without harming healthy surrounding cells. The company's flagship commercial product, NexoBrid, is an FDA-approved orphan biologic utilized globally for the non-surgical debridement of severe thermal burns, effectively reducing hospital stays and complications. Additionally, MediWound is advancing a clinical pipeline featuring EscharEx, an innovative enzymatic treatment targeting chronic and hard-to-heal wounds such as diabetic foot ulcers and venous leg ulcers, backed by strategic partnerships and government research grants.